Status:
COMPLETED
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan
Lead Sponsor:
Hellenic Cooperative Oncology Group
Conditions:
Breast Cancer
Metastatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The study aims to evaluate real-world efficacy and toxicity data of treatment with Trastuzumab deruxtecan (T-DXd), a HER2-targeting ADC and sacituzumab govitecan (SG), a TROP-2-targeting ADC in pretre...
Detailed Description
Antibody-drug conjugates (ADCs) have significantly changed the therapeutic landscape of advanced breast cancer. Trastuzumab deruxtecan (T-DXd), a HER2-targeting ADC and sacituzumab govitecan (SG), a T...
Eligibility Criteria
Inclusion
- Histologically confirmed metastatic/recurrent breast cancer
- 18 years of age
- Triple-negative (TNBC), HER2-positive and/or hormone receptor positive advanced breast cancer
- Treatment with an ADC at any of line of treatment
- Treatment with at least one cycle of T-DXd and/or SG
Exclusion
- NA
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2024
Estimated Enrollment :
312 Patients enrolled
Trial Details
Trial ID
NCT06504719
Start Date
January 1 2023
End Date
September 1 2024
Last Update
September 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hellenic Cooperative Oncology Group
Athens, Greece, 11524